Oppenheimer Reiterates Outperform Rating on Protera Therapeutics (TARA)

Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $25.00 price target on Protera Therapeutics (NASDAQ: TARA).

The analyst commented: "As we look forward to incremental data in NMIBC next quarter, TARA provided positive updates on its development programs for choline deficiency and lymphatic malformations (LMs). IV choline chloride will move into a pivotal study in 1Q25, with newly-announced observational data underscoring the need to address choline deficiency in those dependent on parenteral nutrition. Two of the three patients in the LM registrational trial's first cohort evidenced a complete response after just a single dose of TARA-002, and we look forward to results from currently-enrolling expansion cohorts in 1H25. With incremental efficacy data from the Phase 2 ADVANCED-2 study of '002 in high-grade NMIBC on track for next quarter, we view shares as increasingly compelling as the company makes clinical progress in multiple high-value opportunities."

For an analyst ratings summary and ratings history on Protera Therapeutics click here. For more ratings news on Protera Therapeutics click here.

Shares of Protera Therapeutics closed at $1.70 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Genco Shipping urges shareholders to reject Diana's $24.80 takeover bid
• Darling Ingredients receives US patent for blood glucose collagen peptide